FiercePharma

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...
Insider Monkey

Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
FiercePharma

RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
Yahoo Finance

Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta

GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced positive headline results from a phase IIIb study – Salford Lung Study – on Relvar Ellipta (100/25mcg; furoate/vilanterol) for the ...
Business Wire

Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...
PharmaTimes

GSK’s Relvar Ellipta hits the mark in COPD trial

A "ground-breaking" UK study has shown that GlaxoSmithKline's Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) ...
Stockhouse

Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar ® Ellipta ® (fluticasone ...
Ärzteblatt

RELVAR® ELLIPTA® – Neu im Asthma-Portfolio

Mit RELVAR®* erweitert die BERLIN-CHEMIE AG aktuell ihr Angebot in der Langzeittherapie des Asthma bronchiale: Die modernen Wirkstoffe Fluticason-Furoat und Vilanterol (FF/VI) stehen im ...
wallstreet

Anzeige Ihr Wallstreet-Marktupdate: Alles für den US-Börsenstart – Jetzt anmelden!

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 20, 2013) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese ...
Finanznachrichten

Nachrichten»GSK & Innoviva Announce Approval Of Relvar Ellipta In Japan For COPD

LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Innoviva, Inc. (INVA) announced the Japanese Ministry of Health, Labour and Welfare has approved Relvar Ellipta for the relief of various ...
Business Wire

Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Royalties at $65.6 million in the third quarter of 2022, compared to $65.7 million in the same quarter of 2021, for RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® Announced new $100.0 million share ...
Yahoo Finance

RELVAR(R) ELLIPTA(R) Receives European Marketing Authorisation for the Treatment of Asthma and COPD

COPD: the symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD) with a FEV 1 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular ...